Nanobiotix S.A. (NASDAQ:NBTX) Short Interest Update

Nanobiotix S.A. (NASDAQ:NBTX - Get Free Report) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 9,200 shares, a decline of 68.6% from the February 28th total of 29,300 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 20,100 shares, the short-interest ratio is currently 0.5 days.

Wall Street Analyst Weigh In

Separately, UBS Group raised shares of Nanobiotix to a "hold" rating in a report on Monday, February 17th.

Nanobiotix Stock Performance

NASDAQ:NBTX traded down $0.03 during midday trading on Monday, hitting $3.58. 3,228 shares of the company traded hands, compared to its average volume of 21,525. The firm's fifty day moving average is $3.57 and its 200-day moving average is $3.83. Nanobiotix has a 12-month low of $2.76 and a 12-month high of $7.51.

Institutional Investors Weigh In On Nanobiotix

Several hedge funds and other institutional investors have recently made changes to their positions in NBTX. Millennium Management LLC purchased a new position in shares of Nanobiotix during the 4th quarter worth about $39,000. Jane Street Group LLC purchased a new position in shares of Nanobiotix during the fourth quarter valued at approximately $73,000. Geode Capital Management LLC bought a new position in shares of Nanobiotix during the fourth quarter valued at approximately $29,000. Finally, OLD Mission Capital LLC purchased a new stake in shares of Nanobiotix in the fourth quarter worth approximately $139,000. Hedge funds and other institutional investors own 38.81% of the company's stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.